DJ Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Information on Document Availability
18-Feb-2021 / 08:54 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Aubagne, February 18, 2021
Sartorius Stedim Biotech: Information on Document Availability
Sartorius Stedim Biotech Group's Universal Registration Document 2020 is now available at:
https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations/
news-financial-publications
It contains the following information:
- Business development for fiscal 2020 and the 2021 forecast for the Sartorius Stedim Biotech Group
- Consolidated financial statements for the year ended December 31, 2020
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions
provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own
manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies,
Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has
been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020, the company employed
more than 7,500 people, and earned sales revenue of 1,910 million euros.
Contact
Petra Kirchhoff; Head of Corporate Communications and Investor Relations
Phone: +49(0)551.308.1686; petra.kirchhoff@sartorius.com
=----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file
File: Information on Document Availability
=---------------------------------------------------------------------------------------------------------
Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: info@sartorius-stedim.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
Euronext Ticker: DIM
AMF Category: Annual financial and audit reports / Terms of availability of the annual financial report
EQS News ID: 1169248
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
1169248 18-Feb-2021 CET/CEST
(END) Dow Jones Newswires
February 18, 2021 02:56 ET (07:56 GMT)
